VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Shares in Medpace Holdings, Inc. $MEDP

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,309 shares of the company’s stock, valued at approximately $5,460,000.

A number of other large investors also recently bought and sold shares of the stock. Johnson Financial Group Inc. acquired a new position in shares of Medpace in the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth $30,000. Jones Financial Companies Lllp purchased a new position in shares of Medpace in the 2nd quarter worth $30,000. Finally, Allied Private Wealth LLC purchased a new position in shares of Medpace in the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $590.89 on Wednesday. The company has a market cap of $16.49 billion, a P/E ratio of 34.64, a PEG ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The business’s 50-day simple moving average is $577.04 and its 200 day simple moving average is $502.19.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the business earned $3.10 EPS. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. BMO Capital Markets boosted their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $595.20.

Insider Activity

In other Medpace news, CFO Kevin M. Brady sold 3,400 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the transaction, the chief financial officer directly owned 12,830 shares of the company’s stock, valued at $8,021,829.20. This represents a 20.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director directly owned 27,825 shares in the company, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 134,471 shares of company stock valued at $82,151,311 in the last 90 days. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.